Search Result

Results for "

IGF-1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	IGF-1R (36) ADC Antibody (1) Adenylate Cyclase (2) Akt (1) Anaplastic lymphoma kinase (ALK) (5) Apoptosis (12) Aurora Kinase (1) Autophagy (3) Bcr-Abl (1) Caspase (1) Cholinesterase (ChE) (1) COX (1) Drug Metabolite (4) EGFR (5) FAK (1) G-quadruplex (1) Glucosidase (1) Insulin Receptor (11) Isotope-Labeled Compounds (1) JNK (1) NF-κB (1) PARP (1) Pyk2 (1) ROS Kinase (1) SARS-CoV (1) Small Interfering RNA (siRNA) (6) Somatostatin Receptor (3) Src (1) STAT (1) Telomerase (1) TSH Receptor (1) VEGFR (1)
By Research Areas:	Cancer (38) Cardiovascular Disease (3) Endocrinology (20) Infection (1) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (1)

By Targets:

IGF-1R (36)

ADC Antibody (1)

Adenylate Cyclase (2)

Akt (1)

Anaplastic lymphoma kinase (ALK) (5)

Apoptosis (12)

Aurora Kinase (1)

Autophagy (3)

Bcr-Abl (1)

Caspase (1)

Cholinesterase (ChE) (1)

COX (1)

Drug Metabolite (4)

EGFR (5)

FAK (1)

G-quadruplex (1)

Glucosidase (1)

Insulin Receptor (11)

Isotope-Labeled Compounds (1)

JNK (1)

NF-κB (1)

PARP (1)

Pyk2 (1)

ROS Kinase (1)

SARS-CoV (1)

Small Interfering RNA (siRNA) (6)

Somatostatin Receptor (3)

Src (1)

STAT (1)

Telomerase (1)

TSH Receptor (1)

VEGFR (1)

By Research Areas:

Cancer (38)

Cardiovascular Disease (3)

Endocrinology (20)

Infection (1)

Inflammation/Immunology (3)

Metabolic Disease (2)

Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Inhibitory Antibodies

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: IGF-1R

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-145110

IGF-1R inhibitor-2	IGF-1R	Cancer
IGF-1R inhibitor-2 (example 121) is an insulin-like growth factor-1 receptor (IGF-1R) inhibitor. Downregulation of IGF-1R can reverse the transformed phenotype of tumor cells and potentially render them susceptible to apoptosis ^[1].

HY-RS06614

IGF1 Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
IGF1 Human Pre-designed siRNA Set A contains three designed siRNAs for IGF1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

IGF1 Human Pre-designed siRNA Set A IGF1 Human Pre-designed siRNA Set A

HY-RS06615

IGF1R Human Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
IGF1R Human Pre-designed siRNA Set A contains three designed siRNAs for IGF1R gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

IGF1R Human Pre-designed siRNA Set A IGF1R Human Pre-designed siRNA Set A

HY-RS06616

Igf1r Mouse Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Igf1r Mouse Pre-designed siRNA Set A contains three designed siRNAs for Igf1r gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.

Igf1r Mouse Pre-designed siRNA Set A Igf1r Mouse Pre-designed siRNA Set A

HY-RS06617

Igf1r Rat Pre-designed siRNA Set A	Small Interfering RNA (siRNA)	Others
Igf1r Rat Pre-designed siRNA Set A contains three designed siRNAs for Igf1r gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.

Igf1r Rat Pre-designed siRNA Set A Igf1r Rat Pre-designed siRNA Set A

HY-P99274

Xentuzumab BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody	IGF-1R	Cancer
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands *IGF1* and *IGF2. Xentuzumab inhibits both of IGF1* and *IGF2* growth-promoting signalling and suppresses AKT activation ^[1].

HY-135436

AG 538

IGF-1R Cancer

AG 538 is a potent, competitive inhibitor of IGF-1 receptor kinase, with an IC₅₀ of 400 nM ^[1].

AG 538	IGF-1R	Cancer
AG 538 is a potent, competitive inhibitor of IGF-1 receptor kinase, with an IC₅₀ of 400 nM ^[1].

HY-109155

Paltusotine 1 Publications Verification CRN00808	Somatostatin Receptor	Endocrinology Cancer
Paltusotine (CRN00808) is an orally active, nonpeptide selective somatostatin type 2 (SST2) receptor agonist. Paltusotine has the potential for maintaining GH and IGF-1 levels after depot somatostatin receptor ligand therapy.Paltusotine can be used in research on acromegaly and neuroendocrine tumors ^[1] .

HY-P99294

Ganitumab AMG 479; Human Anti-IGF1R Recombinant Antibody	IGF-1R	Cancer
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (K_D=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer ^[1].

HY-139783

3-Campholenyl-2-butanol	Apoptosis	Others
3-Campholenyl-2-butanol, a synthetic sandalwood odorant, is a selective olfactory receptor OR2AT4 agonist. 3-Campholenyl-2-butanol prolongs human hair growth ex vivo by decreasing apoptosis and increasing production of the anagen-prolonging growth factor IGF-1 in the outer root sheath (ORS) ^[1].

HY-135749

BN201	Others	Neurological Disease Inflammation/Immunology
BN201 promotes neuronal differentiation, the differentiation of precursor cells to mature oligodendrocytes (EC₅₀ of 6.3 μM) in vitro, and the myelination of new axons (EC₅₀ of 16.6 μM). BN201 is able to cross the blood-brain barrier by active transport and activate pathways (IGF-1 pathway) associated with the response to stress and neuron survival. BN201 has potently neuroprotective effects ^[1].

HY-P99165

Teprotumumab	IGF-1R TSH Receptor	Endocrinology
Teprotumumab is an **IGF-1 receptor (IGF-1R)** blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research ^[1].

HY-10191

Linsitinib Maximum Cited Publications 33 Publications Verification OSI-906	IGF-1R Insulin Receptor	Endocrinology Cancer
Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC₅₀s of 35 and 75 nM, respectively ^[1].

HY-P99197

Figitumumab CP-751871	IGF-1R	Cancer
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC₅₀ of 1.8 nM ^[1].

HY-N0908

Ginsenoside Rg5 1 Publications Verification	IGF-1R NF-κB COX	Cardiovascular Disease Inflammation/Immunology Endocrinology Cancer
Ginsenoside Rg5 is the main component of Red ginseng and *IGF-1R* agonist. Ginsenoside Rg5 compets for the binding site of IGF-1R and blocks the binding of *IGF-1* to IGF-1R (IC₅₀ about 90 nM). Ginsenoside Rg5 also inhibits the mRNA expression of COX-2 via suppression of the DNA binding activities of NF-κB p65.

HY-P99867

Dusigitumab

MEDI 573
IGF-1R Others

Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody that specifically targets IGF2 and IGF1 ^[1].

Dusigitumab MEDI 573	IGF-1R	Others
Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody that specifically targets IGF2 and IGF1 ^[1].

HY-P99284

Dalotuzumab MK-0646; h7C10	IGF-1R Apoptosis	Cancer
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting *IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2*-mediated tumor cell proliferation, *IGF-1R* autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo ^[1] .

HY-153485A

Cimdelirsen sodium ISIS 766720 sodium; IONIS-GHR-LRx sodium	Small Interfering RNA (siRNA)	Others
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.

HY-153485

Cimdelirsen ISIS 766720; IONIS-GHR-LRx	Small Interfering RNA (siRNA)	Others
Cimdelirsen is a novel, ligand-conjugated, hepatic-targeted investigative antisense oligonucleotide designed to reduce growth hormone receptor (GHr) synthesis, thereby inhibiting deleterious effects of growth hormone (GH) hypersecretion and reducing circulating insulin-like growth factor-1 (IGF-1) levels in acromegaly patients.

HY-15609

AZD-3463 ALK/IGF1R inhibitor	IGF-1R Anaplastic lymphoma kinase (ALK) Autophagy Apoptosis	Endocrinology Cancer
AZD-3463 (ALK/IGF1R inhibitor) is an orally active *ALK/IGF1R* inhibitor, with a K_i of 0.75 nM for ALK. AZD3463 induces apoptosis and autophagy in neuroblastoma cells ^[1] .

HY-108477

TMPyP4 tosylate 1 Publications Verification TMP 1363	G-quadruplex Telomerase Cholinesterase (ChE) SARS-CoV	Cancer
TMPyP4 tosylate (TMP 1363) is a quadruplex-specific ligand. TMPyP4 tosylate inhibits the interaction between G-quadruplexes and IGF-1. TMPyP4 tosylate is a telomerase inhibitor and inhibits cancer cells proliferation. TMPyP4 tosylate is also a stabilizer of nucleic acid secondary structure and an acetylcholinesterase inhibitor. Besides, TMPyP4 tosylate has antiviral activity against SARS-CoV-2 ^[1] .

HY-P2090

Angiopeptin	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin has the potential for coronary atherosclerosis research ^[1] .

HY-P2090A

Angiopeptin TFA	Somatostatin Receptor Adenylate Cyclase	Cardiovascular Disease
Angiopeptin TFA, a cyclic octapeptide analogue of somatostatin, is a weak sst₂/sst₅ receptor partial agonist with IC₅₀ values of 0.26 nM and 6.92 nM, respectively. Angiopeptin TFA is a potent inhibitor of growth hormone release and insulin-like growth factor-1 (IGF-1) production. Angiopeptin TFA inhibits adenylate cyclase or stimulates extracellular acidification. Angiopeptin TFA has the potential for coronary atherosclerosis research ^[1] .

HY-125102

AZ12253801	IGF-1R	Cancer
AZ12253801 is an ATP-competitive *IGF-1R* tyrosine kinase inhibitor that shows ∼10-fold selectivity over the insulin receptor. AZ12253801 inhibits IGF-1R–driven proliferation in 3T3 mouse fibroblasts (transfected with human IGF-1R) with an IC₅₀ of 17 nmol/L. The IC₅₀ for epidermal growth factor receptor (EGFR)–driven proliferation is 440 nmol/L. Anti-tumor activity.

HY-P99672

Istiratumab MM 141; MM-005	IGF-1R EGFR	Cancer
Istiratumab (M-6495) is bispecific monoclonal antibody targeting *IGF-1R* and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers ^[1] .

HY-15494

Picropodophyllin 15+ Cited Publications AXL1717; Picropodophyllotoxin; PPP	IGF-1R Apoptosis	Endocrinology Cancer
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-18785

Indirubin Derivative E804

Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor (IGF1R), with an IC₅₀ of 0.65 μM for IGF1R.

Indirubin Derivative E804
Indirubin Derivative E804 is a potent inhibitor of Insulin-like Growth Factor 1 Receptor *(IGF1R), with an IC₅₀* of 0.65 μM for IGF1R.

HY-15749

XL228 3 Publications Verification	Aurora Kinase Bcr-Abl IGF-1R Src	Endocrinology Cancer
XL228 is a multi-targeted tyrosine kinase inhibitor with IC₅₀s of 5, 3.1, 1.6, 6.1, 2 nM for Bcr-Abl, Aurora A, *IGF-1R, Src* and Lyn, respectively.

HY-135680

I-OMe-Tyrphostin AG 538 I-OMe-AG 538	IGF-1R	Metabolic Disease Cancer
I-OMe-Tyrphostin AG 538 (I-OMe-AG 538) is a specific inhibitor of *IGF-1R* (insulin-like growth factor-1 receptor tyrosine kinase). I-OMe-Tyrphostin AG 538 inhibits IGF-1R-mediated signaling and is preferentially cytotoxic to nutrient-deprived PANC1 cells. I-OMe-Tyrphostin AG 538 is an ATP-competitive inhibitor of phosphatidylinositol-5-phosphate 4-kinase α (PI5P4Kα), with an IC₅₀ of 1 µM ^[1].

HY-15494S1

Picropodophyllin-d6 AXL1717-d₆; Picropodophyllotoxin-d₆; PPP-d₆	Isotope-Labeled Compounds IGF-1R Apoptosis	Endocrinology Cancer
Picropodophyllin-d₆ (AXL1717-d₆) is deuterium labeled Picropodophyllin. Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC50 of 1 nM.

HY-10262

BMS-536924 3 Publications Verification	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
BMS-536924 is an orally active, competitive and selective insulin-like growth factor receptor (IGF-1R) kinase and insulin receptor (IR) inhibitor with IC₅₀s of 100 nM and 73 nM, respectively. BMS-536924 has anti-cancer activity ^[1] .

HY-10253

AG1024 4 Publications Verification Tyrphostin AG 1024	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
AG1024 (Tyrphostin AG 1024) is a reversible, competitive and selective *IGF-1R* inhibitor with an IC₅₀ of 7 μM. AG1024 inhibits phosphorylation of IR (IC₅₀=57 μM). AG1024 induces apoptosis and has anti-cancer activity ^[1] .

HY-P99218

Robatumumab Sch 717454; 19D12	IGF-1R	Cancer
Robatumumab (Sch 717454) is an anti-human *IGF-1R* (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research ^[1] .

HY-N6611

Chimaphilin	IGF-1R	Infection Inflammation/Immunology Cancer
Chimaphilin is an *IGF-1R* inhibitor (IC₅₀: 0.086 μM). Chimaphilin has antifungal, antioxidant and anticancer activities. Chimaphilin inhibits the growth of both drug-sensitive and drug-resistant osteosarcoma cell lines. Chimaphilin can induce cancer cell apoptosis. Chimaphilin is a main component of pyrola ^[1] .

HY-B0794A

AZ7550 hydrochloride	EGFR IGF-1R Drug Metabolite	Endocrinology Cancer
AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of *IGF1R* with an IC₅₀ of 1.6 μM.

HY-B0794B

AZ7550 Mesylate 1 Publications Verification AZ7550 trimesylate salt	EGFR IGF-1R Drug Metabolite	Endocrinology Cancer
AZ7550 Mesylate is an active metabolite of AZD9291 and inhibits the activity of *IGF1R* with an IC₅₀ of 1.6 μM.

HY-B0794

AZ7550

EGFR IGF-1R Drug Metabolite Endocrinology Cancer

AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC₅₀ of 1.6 μM.

AZ7550	EGFR IGF-1R Drug Metabolite	Endocrinology Cancer
AZ7550 is an active metabolite of AZD9291 and inhibits the activity of *IGF1R* with an IC₅₀ of 1.6 μM.

HY-50866

NVP-AEW541 5+ Cited Publications AEW541	IGF-1R Insulin Receptor Autophagy	Endocrinology Cancer
NVP-AEW541 (AEW541 ) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC₅₀ value of 0.15 μM. NVP-AEW541 also inhibits InsR, IC₅₀ with a value of 0.14 μM. NVP-AEW541 has antitumor activity ^[1].

HY-13203

NVP-TAE 226 5+ Cited Publications TAE226	FAK Pyk2 IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
NVP-TAE 226 (TAE226) is a potent and ATP-competitive dual FAK and *IGF-1R* inhibitor with IC₅₀s of 5.5 nM and 140 nM, respectively. NVP-TAE 226 (TAE226) also effectively inhibits Pyk2 and insulin receptor (InsR) with IC₅₀s of 3.5 nM and 44 nM, respectively ^[1] .

HY-15656

Ceritinib 25+ Cited Publications LDK378	Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R	Endocrinology Cancer
Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC₅₀ of 200 pM. Ceritinib (LDK378) also inhibits *IGF-1R, InsR, and STK22D* with IC₅₀ values of 8, 7, and 23 nM, respectively. Ceritinib (LDK378) shows great antitumor potency ^[1] .

HY-15656A

Ceritinib dihydrochloride 25+ Cited Publications LDK378 dihydrochloride	Anaplastic lymphoma kinase (ALK) Insulin Receptor IGF-1R	Endocrinology Cancer
Ceritinib dihydrochloride (LDK378 dihydrochloride) is a selective, orally bioavailable and ATP-competitive ALK tyrosine kinase inhibitor with an IC₅₀ of 200 pM. Ceritinib dihydrochloride (LDK378 dihydrochloride) also inhibits *IGF-1R, InsR, and STK22D* with IC₅₀ values of 8, 7, and 23 nM, respectively. Ceritinib dihydrochloride (LDK378 dihydrochloride) shows great antitumor potency ^[1] .

HY-50866B

NVP-AEW541 dihydrochloride AEW541 dihydrochloride	IGF-1R Insulin Receptor Autophagy	Cancer
NVP-AEW541 dihydrochloride (AEW541 dihydrochloride) is an orally active inhibitor of the insulin-like growth factor 1 receptor (IGF-1R) with an IC₅₀ value of 0.15 μM. NVP-AEW541 dihydrochloride also inhibits InsR, IC₅₀ with a value of 0.14 μM. NVP-AEW541 dihydrochloride has antitumor activity ^[1].

HY-10252

NVP-ADW742 2 Publications Verification ADW742; GSK 552602A; ADW	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
NVP-ADW742 (ADW742) is an orally active, selective IGF-1R tyrosine kinase inhibitor with an IC₅₀ of 0.17 μM. NVP-ADW742 inhibits insulin receptor (InsR) with an IC₅₀ of 2.8 μM. NVP-ADW742 induces pleiotropic antiproliferative/proapoptotic biologic sequelae in tumor cells ^[1] .

HY-10200

BMS-754807 5+ Cited Publications	IGF-1R Insulin Receptor	Endocrinology Cancer
BMS-754807 is a potent and reversible *IGF-1R*/IR inhibitor (IC₅₀=1.8 and 1.7 nM, respectively; K_i=<2 nM for both). BMS-754807 also shows potent activities against Met, RON, TrkA, TrkB, AurA, and AurB with IC₅₀ values of 6, 44, 7, 4, 9, and 25 nM, respectively ^[1].

HY-10524

GSK1904529A 5+ Cited Publications	IGF-1R Insulin Receptor Apoptosis	Endocrinology Cancer
GSK1904529A is a potent, selective, orally active, and ATP-competitive inhibitor of insulin-like growth factor-1 receptor (IGF-1R) and insulin receptor (IR), with IC₅₀s of 27 and 25 nM, respectively. GSK1904529A shows poor activity (IC₅₀>1 μM) in 45 other serine/threonine and tyrosine kinases. GSK1904529A exhibits anti-tumor activity ^[1] .

HY-13326

ASP3026 5 Publications Verification	Anaplastic lymphoma kinase (ALK) Apoptosis ROS Kinase Caspase PARP IGF-1R STAT Akt JNK	Cancer
ASP3026 is a selective and orally active inhibitor of anaplastic lymphoma kinase (ALK). ASP3026 is a selective and oral active anaplastic lymphoma kinase (ALK) inhibitor with a IC₅₀ value of 3.5 nM. ASP3026 can inhibit the phosphorylation of *IGF-1R, STAT3, AKT* and JNK proteins, and induce the cleavage of caspase 3 and PARP. It also inhibited ROS and ACK. ASP3026 can be used in anti-tumor research ^[1] .

HY-116624

MAZ51 2 Publications Verification	VEGFR Apoptosis	Cancer
MAZ51 is a selective inhibitor of VEGFR-3 (Flt-4) tyrosine kinase. MAZ51 inhibits VEGF-C-induced activation of VEGFR-3 without blocking VEGF-C-mediated stimulation of VEGFR2. MAZ51 had no effect on ligand-induced autophosphorylation of EGFR, IGF-1R and PDGFRβ. MAZ51 blocks proliferation and induces apoptosis in a wide variety of tumor cells. Antitumor activity ^[1] .

HY-100349

SU4312
SU4312 is the racemate of (Z)-SU4312 and (E)-SU4312. (Z)-SU4312 inhibits PDGFR and FLK-1 with IC₅₀s of 19.4 and 0.8 μM, respectively. (E)-SU4312 inhibits PDGFR, FLK-1, EGFR, HER-2, and IGF-1R with IC₅₀s of 24.2, 5.2, 18.5, 16.9 and 10.0 μM, respectively ^[1].

HY-P990084

Veligrotug

IGF-1R Cancer

Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody ^[1].

HY-P99712

Lonigutamab hz208F2-4	IGF-1R ADC Antibody	Cancer
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody that can be used for the synthesis of antibody–agent conjugates (ADC) ^[1].

Cat. No.	Product Name

HY-L124

Anti-Prostate Cancer Compound Library

2295 compounds

Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development and progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, and mTOR and other signaling pathways. These provide potential therapeutic target in prostate cancer treatment.

MCE offers a unique collection of 2295 compounds with identified and potential anti-prostate cancer activity. MCE Anti-Prostate Cancer Compound Library is a useful tool for anti-prostate cancer drugs screening and other related research.

HY-L034

Anti-Aging Compound Library

4352 compounds

Aging is a complex biological process characterized by functional decline of tissues and organs, structural degeneration, and reduced adaptability and resistance, all of which contribute to an increase in morbidity and mortality caused by multiple chronic diseases, such as Alzheimer's disease, cancer, and diabetes. Many theories, which fall into two main categories: programmed and error theories, have been proposed to explain the process of aging, but neither of them appears to be fully satisfactory. The programmed theories imply that aging relies on specific gene regulation, and the error theories emphasize the internal and environmental damages accumulated to living organisms. The damage theories proposed the nine hallmarks that were generally considered to contribute to the aging process: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

MCE Anti-Aging Compound Library contains 4352 compounds, mainly targeting Sirtuin, mTOR, IGF-1R, AMPK, p53, Telomerase, Mitophagy, Mitochondrial Metabolism, COX, Cytochrome P450, Oxidase, etc. This library is a useful tool for anti-aging research.

Cat. No.	Product Name	Target	Research Area

HY-P99274

Xentuzumab BI 836845; Anti-Human IGF1 and IGF2 Recombinant Antibody	IGF-1R	Cancer
Xentuzumab (Anti-Human IGF1 and IGF2 Recombinant Antibody; BI836845) is a recombinant a human monoclonal antibody that targets IGF ligands *IGF1* and *IGF2. Xentuzumab inhibits both of IGF1* and *IGF2* growth-promoting signalling and suppresses AKT activation ^[1].

HY-P99294

Ganitumab AMG 479; Human Anti-IGF1R Recombinant Antibody	IGF-1R	Cancer
Ganitumab (AMG 479) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (K_D=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. Ganitumab can be used in research of cancer ^[1].

HY-P99165

Teprotumumab	IGF-1R TSH Receptor	Endocrinology
Teprotumumab is an **IGF-1 receptor (IGF-1R)** blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab attenuates TSH-dependent IL-6 and IL-8 expression and Akt phosphorylation. Teprotumumab can be used for thyroid-associated ophthalmopathy research ^[1].

HY-P99197

Figitumumab CP-751871	IGF-1R	Cancer
Figitumumab (CP-751871) is a potent and fully human monoclonal anti–insulin-like growth factor 1 receptor (IGF1R) antibody. Figitumumab prevents IGF1 from binding to IGF1R with an IC₅₀ of 1.8 nM ^[1].

HY-P99867

Dusigitumab

MEDI 573
IGF-1R Others

Dusigitumab (MEDI 573) is a human IgG2λ monoclonal antibody that specifically targets IGF2 and IGF1 ^[1].

HY-P99284

Dalotuzumab MK-0646; h7C10	IGF-1R Apoptosis	Cancer
Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting *IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2*-mediated tumor cell proliferation, *IGF-1R* autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo ^[1] .

HY-P99672

Istiratumab MM 141; MM-005	IGF-1R EGFR	Cancer
Istiratumab (M-6495) is bispecific monoclonal antibody targeting *IGF-1R* and ErbB3. Istiratumab induces IGF-1R and ErbB3 receptor degradation through the proteasome pathway Istiratumab can be used for research of cancers ^[1] .

HY-P99218

Robatumumab Sch 717454; 19D12	IGF-1R	Cancer
Robatumumab (Sch 717454) is an anti-human *IGF-1R* (insulin-like growth factor receptor-1) antibody. Robatumumab shows anti-tumor activity and anti-proliferative activity to cancer cells. Robatumumab can be used in osteosarcoma and Ewing sarcoma research ^[1] .

HY-P990084

Veligrotug

IGF-1R Cancer

Veligrotug is an IgG1-kappa, anti-IGF1R (insulin-like growth factor 1 receptor, CD221) chimeric monoclonal antibody ^[1].

HY-P99712

Lonigutamab hz208F2-4	IGF-1R ADC Antibody	Cancer
Lonigutamab (hz208F2-4) is a humanized anti-IGF-1R monoclonal antibody that can be used for the synthesis of antibody–agent conjugates (ADC) ^[1].

HY-P99189

Cixutumumab IMC-A12; NSC742460	Inhibitory Antibodies	Cancer
Cixutumumab (IMC-A12) is a human anti-IGF-1R monoclonal antibody with high affinity that inhibits ligand-dependent receptor activation and downstream signaling. Cixutumumab also mediates the internalization and degradation of *IGF-IR*. Cixutumumab shows broad-spectrum anti-tumour activity and can be used in studies of cancers such as lung cancer, malignancies, leukaemia, non-small cell lung cancer and prostate cancer ^[1].

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0908

Ginsenoside Rg5 1 Publications Verification	Cardiovascular Disease Panax ginseng C. A. Meyer Triterpenes Structural Classification Classification of Application Fields Terpenoids Source classification Plants Inflammation/Immunology Disease Research Fields Endocrinology Araliaceae	IGF-1R NF-κB COX
Ginsenoside Rg5 is the main component of Red ginseng and *IGF-1R* agonist. Ginsenoside Rg5 compets for the binding site of IGF-1R and blocks the binding of *IGF-1* to IGF-1R (IC₅₀ about 90 nM). Ginsenoside Rg5 also inhibits the mRNA expression of COX-2 via suppression of the DNA binding activities of NF-κB p65.

HY-15494

Picropodophyllin 15+ Cited Publications AXL1717; Picropodophyllotoxin; PPP	Structural Classification Classification of Application Fields Source classification Lignans Dysosma versipellis (Hance) M. Cheng ex Ying Phenylpropanoids Plants Berberidaceae Disease Research Fields Endocrinology	IGF-1R Apoptosis
Picropodophyllin (AXL1717) is a selective insulin-like growth factor-1 receptor (IGF-1R) inhibitor with an IC₅₀ of 1 nM.

HY-B0025

Voglibose	Structural Classification Microorganisms Classification of Application Fields Source classification Metabolic Disease Disease Research Fields Saccharides	Glucosidase
Voglibose is an orally active alpha-glucosidase inhibitor that prevents the development of colorectal precancerous lesions induced by obesity and diabetes. Voglibose reduces oxidative stress in an inflammatory environment and inhibits the insulin-like growth factor/insulin-like growth factor-1 receptor (IGF/IGF-1R) functional axis.

HY-N6611

Chimaphilin	Quinones Structural Classification Passifloraceae Source classification Passiflora incarnata L. Plants Naphthalene Quinones	IGF-1R
Chimaphilin is an *IGF-1R* inhibitor (IC₅₀: 0.086 μM). Chimaphilin has antifungal, antioxidant and anticancer activities. Chimaphilin inhibits the growth of both drug-sensitive and drug-resistant osteosarcoma cell lines. Chimaphilin can induce cancer cell apoptosis. Chimaphilin is a main component of pyrola ^[1] .

Recombinant Proteins Recommended:

Insulin-like Growth Factor I (IGF-1)

Species:	Human (14) Rat (1) Mouse (6) Cynomolgus (1)
Tag:	His (13) Tag Free (9) Avi (2) GST (1) Fc (1)
Source:	HEK293 (7) P. pastoris (2) Sf9 insect cells (1) E. coli (13)

Cat. No.	Compare	Product Name	Species	Source

HY-P700093AF

	*Animal-Free IGF-I/IGF-1* Protein, Human (His)** 1 Publications Verification Somatamedin C; IGF-IA; Insulin-Like Growth Factor I; IGF-I; Mechano Growth Factor; MGF; Somatomedin-C; IGF1; IBP1	Human	E. coli
	The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. Animal-Free IGF-I/IGF-1 Protein, Human (His) is the recombinant human-derived animal-FreeIGF-I/IGF-1 protein, expressed by E. coli , with C-His labeled tag. The total length of Animal-Free IGF-I/IGF-1 Protein, Human (His) is 70 a.a., with molecular weight of ~8.59 kDa.

HY-P700478

	IGF-I/IGF-1 Protein, Human (P. pastoris, N-His) 1 Publications Verification Insulin-Like Growth Factor I; IGF-I; Mechano Growth Factor; MGF; Somatomedin-C; IGF1; IBP1	Human	P. pastoris
	The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. IGF-I/IGF-1 Protein, Human (P. pastoris, N-His) is the recombinant human-derived IGF-I/IGF-1 protein, expressed by P. pastoris , with N-6*His labeled tag. The total length of IGF-I/IGF-1 Protein, Human (P. pastoris, N-His) is 70 a.a., with molecular weight of 9.7 kDa.

HY-P70788

	IGF-I/IGF-1 Protein, Human (G49-A118) 5 Publications Verification Insulin-Like Growth Factor I; IGF-I; Mechano Growth Factor; MGF; Somatomedin-C; IGF1; IBP1	Human	E. coli
	The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. IGF-I/IGF-1 Protein, Human (G49-A118) is the recombinant human-derived IGF-I/IGF-1 protein, expressed by E. coli , with tag free. The total length of IGF-I/IGF-1 Protein, Human (G49-A118) is 70 a.a., with molecular weight of ~9.0 kDa.

HY-P701241

	IGF-I Protein, Salmon IGF1; IGF-1; insulin-like growth factor 1; Insulin-like growth factor I; Somatomedin C; somatomedin-C	Others	E. coli
	IGF-I protein is similar to insulin and exerts effective growth-promoting activity as a ligand of IGF1R. Binding to the α subunit of IGF1R activates intrinsic tyrosine kinase, triggering autophosphorylation of the β subunit. IGF-I Protein, Salmon is the recombinant IGF-I protein, expressed by E. coli , with tag free. The total length of IGF-I Protein, Salmon is 70 a.a., with molecular weight of ~8 kDa.

HY-P70787

	IGF-I/IGF-1 Protein, Human (67a.a) Insulin-Like Growth Factor I; IGF-I; Mechano Growth Factor; MGF; Somatomedin-C; IGF1; IBP1	Human	E. coli
	The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. IGF-I/IGF-1 Protein, Human (67a.a) is the recombinant human-derived IGF-I/IGF-1 protein, expressed by E. coli , with tag free. The total length of IGF-I/IGF-1 Protein, Human (67a.a) is 67 a.a., with molecular weight of ~9.0 kDa.

HY-P7203

	IGF-I/IGF-1 Protein, Rat 1 Publications Verification rRtIGF-I; Somatomedin C; IGF1; Mechano growth factor	Rat	E. coli
	IGF-I/IGF-1 Protein, Rat has somatomedin activity and ability to potently promote neuronal survival.

HY-P70698A

	IGF-I/IGF-1 Protein, Mouse (N-His) IGF1; IGF-1; insulin-like growth factor 1; Insulin-like growth factor I; Somatomedin C; somatomedin-C	Mouse	E. coli
	The IGF-I/IGF-1 protein is structurally similar to insulin and has potent growth-promoting activity. As a physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts, exceeding the efficacy of insulin at lower concentrations. IGF-I/IGF-1 Protein, Mouse (N-His) is the recombinant mouse-derived IGF-I/IGF-1 protein, expressed by E. coli , with N-6*His labeled tag. The total length of IGF-I/IGF-1 Protein, Mouse (N-His) is 70 a.a., with molecular weight of ~10 kDa.

HY-P70698

	IGF-I/IGF-1 Protein, Mouse (His) IGF1; IGF-1; insulin-like growth factor 1; Insulin-like growth factor I; Somatomedin C; somatomedin-C	Mouse	E. coli
	IGF-I/IGF-1 Protein, Mouse (His) is a mitogenic cytokine, binds to IGF type 1 receptor, and modulates growth in many tissues, such as nervous tissue, lymphoid tissue, reproductive tissue, smooth muscle, endothelium, and bone. IGF1 also mediates neuroprotective mechanism.

HY-P72256

	IGF-I R Protein, Human (His) CD221; CD221 antigen ; IGF 1 receptor; IGF 1R; IGF I receptor; IGF-I receptor; IGF1r; IGF1R_HUMAN; IGFIR; IGFIRC; IGFR; Insulin like growth factor 1 receptor; Insulin like growth factor 1 receptor precursor; Insulin-like growth factor 1 receptor beta chain; Insulin-like growth factor I receptor; JTK13; MGC142170; MGC142172; MGC18216; Soluble IGF1R variant 1; Soluble IGF1R variant 2	Human	E. coli
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (His) is the recombinant human-derived IGF-I R protein, expressed by E. coli , with N-6*His labeled tag. The total length of IGF-I R Protein, Human (His) is 169 a.a., with molecular weight of ~23.4 kDa.

HY-P78458

	IGF-I R Protein, Human (HEK293, His-Avi) CD221; IGF1R; IGF-1R; IGF-I R; IGF-I receptor; IGFIR; IGFR; JTK13; MGC142170; MGC142172; MGC18216	Human	HEK293
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (HEK293, His-Avi) is the recombinant human-derived IGF-I R protein, expressed by HEK293, with C-Avi, C-His labeled tag. The total length of IGF-I R Protein, Human (HEK293, His-Avi) is 902 a.a., with molecular weight of 110-130 kDa (alpha subunit) & 52-55 kDa (beta subunit), respectively.

HY-P78142

	IGF-I R Protein, Human (Biotinylated, HEK293, His-Avi) CD221; IGF1R; IGF-1R; IGF-I R; IGF-I receptor; IGFIR; IGFR; JTK13; MGC142170; MGC142172; MGC18216	Human	HEK293
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived IGF-I R protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of IGF-I R Protein, Human (Biotinylated, HEK293, His-Avi) is 902 a.a., with molecular weight of 110-120 kDa (alpha subunit) & 52-55 kDa (beta subunit), respectively.

HY-P78586

	IGF-I R Protein, Cynomolgus (HEK293, His) IGF1R; IGFR; JTK13; CD221; MGC142170; MGC142172; MGC18216	Cynomolgus	HEK293
	The IGF-I R protein is a receptor tyrosine kinase that mediates the effects of insulin-like growth factor 1 (IGF1) and has high affinity for IGF1. Upon ligand binding, IGF1R is activated, leading to autophosphorylation and tyrosine phosphorylation of substrates, including IRS1/2, Shc, and 14-3-3 proteins. IGF-I R Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived IGF-I R protein, expressed by HEK293 , with C-His labeled tag. The total length of IGF-I R Protein, Cynomolgus (HEK293, His) is 878 a.a., with molecular weight (glycosylation form) of 48-58 kDa (β subunit) & 100-115 kDa (α subunit) & 130-150 kDa, respectively.

HY-P78723

	IGF-I R Protein, Mouse (HEK293, His) IGF1R; IGFR; JTK13; CD221; MGC142170; MGC142172; MGC18216	Mouse	HEK293
	The IGF-I R protein, a receptor tyrosine kinase, mediates insulin-like growth factor 1 (IGF1) actions, with high affinity for IGF1. Upon ligand binding, IGF1R activates, leading to autophosphorylation and tyrosine phosphorylation of substrates, including IRS1/2, Shc, and 14-3-3 proteins. Phosphorylation initiates PI3K-AKT/PKB and Ras-MAPK pathways, regulating proliferation and apoptosis. IGF1R signals through JAK/STAT, activating STAT3, contributing to its transforming activity. It also activates JNK and inhibits JNK activation, forming a hybrid receptor with INSR to bind IGF1. IGF-I R Protein, Mouse (HEK293, His) is the recombinant mouse-derived IGF-I R protein, expressed by HEK293, with C-His labeled tag. The total length of IGF-I R Protein, Mouse (HEK293, His) is 906 a.a., with molecular weight of 110-140 & 50-65 kDa, respectively.

HY-P72606

	IGF-I R Protein, Human (HEK293, His) Insulin-like growth factor 1 receptor; IGF-I receptor; IGF1R; CD221	Human	HEK293
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (HEK293, His) is the recombinant human-derived IGF-I R protein, expressed by HEK293 , with C-6*His labeled tag. The total length of IGF-I R Protein, Human (HEK293, His) is 902 a.a., with molecular weight of 100-130 & 54 kDa, respectively.

HY-P73137

	IGF-I R Protein, Human (sf9, His-GST) Insulin-like growth factor 1 receptor; IGF-I receptor; CD221; IGF1R	Human	Sf9 insect cells
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (sf9, His-GST) is the recombinant human-derived IGF-I R protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of IGF-I R Protein, Human (sf9, His-GST) is 414 a.a., with molecular weight of ~74.6 kDa.

HY-P74442

	IGF-I R Protein, Human (HEK293, His, solution) Insulin-like growth factor 1 receptor; IGF-I receptor; CD221; IGF1R	Human	HEK293
	IGF-I receptor (IGF1R) mediates insulin-like growth factor effects, binding strongly to IGF1. Activation triggers PI3K-AKT/PKB and Ras-MAPK pathways, influencing cell survival, protein synthesis, and proliferation. IGF1R also signals through JAK/STAT, inhibiting JNK activation. Hybrid receptors show variable binding to IGF1 and insulin. IGF-I R Protein, Human (HEK293, His, solution) is the recombinant human-derived IGF-I R protein, expressed by HEK293 , with C-His labeled tag. The total length of IGF-I R Protein, Human (HEK293, His, solution) is 902 a.a., with molecular weight of ~150 kDa.

HY-P7070

IGF-I/IGF-1 Protein, Mouse

4 Publications Verification

rMuIGF-1; IGF-IA; Somatamedin C; MGF; IGF-I
Mouse E. coli

IGF-I/IGF-1 Protein, Mouse is a mitogenic cytokine.

HY-P7018

	IGF-I/IGF-1 Protein, Human (70a.a) Maximum Cited Publications 9 Publications Verification rHuIGF-1; IGF-IA; Somatamedin C; MGF; IGF-I	Human	E. coli
	IGF-I/IGF-1 Protein, Human (70a.a) is a mitogenic cytokine, binds to IGF type 1 receptor, and modulates growth in many tissues, such as nervous tissue, lymphoid tissue, reproductive tissue, smooth muscle, endothelium, and bone; IGF-I/IGF-1 Protein also mediates neuroprotective mechanism.

HY-P74843

	IGF-I/IGF-1 Protein, Mouse (P.pastoris) Insulin-like growth factor I; IGF-I; MGF; Somatomedin-C; IBP1	Mouse	P. pastoris
	IGF-I/IGF-1 Protein, part of the insulin family, is highlighted. IGF-I/IGF-1 Protein, Mouse (P.pastoris) is the recombinant mouse-derived IGF-I/IGF-1 protein, expressed by P. pastoris, with tag free. The total length of IGF-I/IGF-1 Protein, Mouse (P.pastoris) is 70 a.a., with molecular weight of ~7.7 kDa.

HY-P73136

	IGF-I/IGF-1 Protein, Human (HEK293, hFc) Insulin-like growth factor I; IGF-I; MGF; Somatomedin-C; IBP1	Human	HEK293
	The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. IGF-I/IGF-1 Protein, Human (HEK293, hFc) is the recombinant human-derived IGF-I/IGF-1 protein, expressed by HEK293 , with N-hFc labeled tag. The total length of IGF-I/IGF-1 Protein, Human (HEK293, hFc) is 70 a.a., with molecular weight of 35-40 kDa.

HY-P70783

	*LR3 IGF-I/IGF-1* Protein, Human (83a.a, E51R)** Long R3 IGF-I; Insulin-like growth factor I; MGF; Somatomedin-C; IBP1	Human	E. coli
	The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. LR3 IGF-I/IGF-1 Protein, Human (83a.a, E51R) is the recombinant human-derived LR3 IGF-I/IGF-1 protein, expressed by E. coli , with tag free. and E51R, , , , mutation. The total length of LR3 IGF-I/IGF-1 Protein, Human (83a.a, E51R) is 70 a.a., with molecular weight of ~11.0 kDa.

HY-P70783G

	*GMP LR3 IGF-I/IGF-1* Protein, Human (83a.a, E51R)** Long R3 IGF-I; Insulin-like growth factor I; MGF; Somatomedin-C; IBP1	Human	E. coli
	The LR3 IGF-I/IGF-1 protein is similar to insulin and has potent growth-promoting activity that exceeds the efficacy of insulin. As a potential physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts even at significantly lower concentrations than insulin. GMP LR3 IGF-I/IGF-1 Protein, Human (83a.a, E51R) is the recombinant human-derived LR3 IGF-I/IGF-1 protein, expressed by E. coli , with tag free. The total length of GMP LR3 IGF-I/IGF-1 Protein, Human (83a.a, E51R) is 70 a.a., with molecular weight of ~11 kDa.

HY-P70698AF

	*Animal-Free IGF-I/IGF-1* Protein, Mouse (His)** rMuIGF-1; IGF-IA; Somatamedin C; MGF; IGF-I	Mouse	E. coli
	The IGF-I/IGF-1 protein is structurally similar to insulin and has potent growth-promoting activity. As a physiological regulator, it stimulates glucose transport and glycogen synthesis in osteoblasts, exceeding the efficacy of insulin at lower concentrations. Animal-Free IGF-I/IGF-1 Protein, Mouse (His) is the recombinant mouse-derived animal-FreeIGF-I/IGF-1 protein, expressed by E. coli , with C-His labeled tag. The total length of Animal-Free IGF-I/IGF-1 Protein, Mouse (His) is 70 a.a., with molecular weight of ~8.61 kDa.

Cat. No.	Product Name	Chemical Structure